Antibody, immunoassay and method for prostate cancer detection

US7872104B2 · kind B2 · utility

Assignee

• Arctic Partners Oy · FI

Inventors

• Kim Pettersson · Turku, FI
• Hans Lilja · Skellefteå, SE
• Timo Lovgren · Turku, FI
• Pauliina Niemelä · Turku, FI

Key dates

• Filing date: Sep 26, 2001
• Grant date: Jan 18, 2011
• Expiry date: Jan 20, 2023

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/57434
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.